title: Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.
abstract: Histology of malignant glioma depicts dense proliferative areas rich in angiogenesis as well as dissemination of neoplastic cells into adjacent brain tissue. Although the mechanisms that trigger transition from proliferative to invasive phenotypes are complex, the dichotomy of cell proliferation and migration, the "Go or Grow" hypothesis, argues for specific and coordinated regulation of these phenotypes. We investigated transcriptional elements that accompany the phenotypes of migration and proliferation, and consider the therapeutic significance of the "Go or Grow" hypothesis. Interrogation of matched core and rim regions from human glioblastoma biopsy specimens in situ (n = 44) revealed higher proliferation (Ki67 labeling index) in cells residing at the core compared to the rim. Profiling activated transcription factors in a panel of migration-activated versus migration-restricted GBM cells portrayed strong NF-κB activity in the migratory cell population. In contrast, increased c-Myc activity was found in migration-restricted proliferative cells. Validation of transcriptional activity by NF-κB- or c-Myc-driven GFP or RFP, respectively, showed an increased NF-κB activity in the active migrating cells, whereas the proliferative, migration restricted cells displayed increased c-Myc activity. Immunohistochemistry on clinical specimens validated a robust phosphorylated c-Myc staining in tumor cells at the core, whereas increased phosphorylated NF-κB staining was detected in the invasive tumor cells at the rim. Functional genomics revealed that depletion of c-Myc expression by siRNA oligonucleotides reduced cell proliferation in vitro, but surprisingly, cell migration was enhanced significantly. Conversely, inhibition of NF-κB by pharmacological inhibitors, SN50 or BAY-11, decreased both cell migration in vitro and invasion ex vivo. Notably, inhibition of NF-κB was found to have no effect on the proliferation rate of glioma cells. These findings suggest that the reciprocal and coordinated suppression/activation of transcription factors, such as c-Myc and NF-κB may underlie the shift of glioma cells from a "growing-to-going" phenotype.
authors: Translational Genomics Research Institute, Phoenix, Arizona, United States of America.
authors: Harshil D
authors: HD
authors: Dhruv
authors: Wendy S
authors: WS
authors: McDonough Winslow
authors: Brock
authors: B
authors: Armstrong
authors: Serdar
authors: S
authors: Tuncali
authors: Jenny
authors: J
authors: Eschbacher
authors: Kerri
authors: K
authors: Kislin
authors: Joseph C
authors: JC
authors: Loftus
authors: Nhan L
authors: NL
authors: Tran
authors: Michael E
authors: ME
authors: Berens
mesh_terms: D002453:Cell Cycle / Q000235:genetics; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D016000:Cluster Analysis; D020869:Gene Expression Profiling; D055785:Gene Knockdown Techniques; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005910:Glioma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000235:genetics; D016328:NF-kappa B / Q000378:metabolism; D009361:Neoplasm Invasiveness; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism*; D015533:Transcriptional Activation
chemical_list: D019394:Ki-67 Antigen; D016328:NF-kappa B; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D014157:Transcription Factors
references: Annu Rev Cell Dev Biol. 2000;16:653-99
references: 11031250
references: Clin Exp Metastasis. 1994 Nov;12(6):405-15
references: 7923993
references: Neoplasia. 2005 Sep;7(9):862-72
references: 16229809
references: Int J Cancer. 1996 Jul 17;67(2):275-82
references: 8760599
references: Exp Cell Res. 2010 May 1;316(8):1429-37
references: 20382143
references: J Biol Chem. 1995 Jun 16;270(24):14255-8
references: 7782278
references: Nat Rev Neurol. 2009 Nov;5(11):610-20
references: 19826401
references: J Neurooncol. 2004 Nov;70(2):217-28
references: 15674479
references: Exp Cell Res. 2000 Aug 25;259(1):86-95
references: 10942581
references: Nature. 1999 Sep 2;401(6748):86-90
references: 10485711
references: Semin Cancer Biol. 2006 Aug;16(4):253-64
references: 16904903
references: J Clin Oncol. 2003 Apr 15;21(8):1624-36
references: 12697889
references: Mol Cancer Ther. 2009 Jun;8(6):1505-14
references: 19509258
references: Oncogene. 2006 Oct 30;25(51):6706-16
references: 17072323
references: J Neurosci. 1998 Dec 15;18(24):10356-65
references: 9852573
references: Oncogene. 1999 May 13;18(19):3004-16
references: 10378696
references: Biochem Pharmacol. 2011 Feb 1;81(3):412-24
references: 21040711
references: Nature. 2010 Jan 21;463(7279):318-25
references: 20032975
references: Cancer Res. 2004 May 1;64(9):3179-85
references: 15126357
references: Expert Rev Mol Diagn. 2006 Jul;6(4):613-26
references: 16824034
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93
references: 17971532
references: Neurosurgery. 1995 Aug;37(2):294-301; discussion 301-2
references: 7477782
references: Cancer Res. 2006 May 15;66(10):5487-94
references: 16707478
references: Mol Cancer Res. 2010 Nov;8(11):1558-67
references: 20881009
references: Nat Rev Cancer. 2002 Oct;2(10):740-9
references: 12360277
references: Neoplasia. 2009 Apr;11(4):377-87
references: 19308292
references: J Neurooncol. 2001 Jun;53(2):161-76
references: 11716068
references: Neoplasia. 2005 Jan;7(1):7-16
references: 15720813
references: Nature. 1990 Apr 12;344(6267):678-82
references: 2157987
references: Nat Rev Cancer. 2002 Apr;2(4):301-10
references: 12001991
references: Pediatr Res. 2006 Apr;59(4 Pt 2):54R-8R
references: 16549549
references: Cell Mol Life Sci. 2002 Aug;59(8):1317-26
references: 12363035
references: J Oral Pathol Med. 2000 Oct;29(9):426-31
references: 11016684
references: Methods Mol Med. 2004;88:219-24
references: 14634232
references: Neurotherapeutics. 2009 Jul;6(3):447-57
references: 19560735
references: Cancer Res. 2006 Oct 1;66(19):9535-42
references: 17018610
references: Am J Pathol. 2005 Aug;167(2):565-76
references: 16049340
references: Mol Cancer Res. 2009 Nov;7(11):1871-81
references: 19861406
references: Front Biosci. 1998 Feb 15;3:d250-68
references: 9468463
references: Mol Cell Biol. 1999 Jan;19(1):1-11
references: 9858526
references: Eur J Histochem. 2002;46(4):377-80
references: 12597623
references: Cancer Res. 2011 Apr 15;71(8):3066-75
references: 21363911
references: Math Med Biol. 2012 Mar;29(1):49-65
references: 20610469
references: Acta Neuropathol. 2007 Nov;114(5):443-58
references: 17805551
references: Biochem Pharmacol. 2004 Sep 15;68(6):1071-80
references: 15313403
references: Cell Mol Life Sci. 2007 Feb;64(4):458-78
references: 17260089
references: Cancer Res. 2004 Nov 15;64(22):8271-5
references: 15548694
references: J Biol Chem. 1997 Aug 22;272(34):21096-103
references: 9261113
references: Genes Dev. 2000 Oct 1;14(19):2501-14
references: 11018017
references: Oncogene. 2006 Oct 30;25(51):6817-30
references: 17072330
references: Oncogene. 1999 May 13;18(19):2934-41
references: 10378690